Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01963052 (Clinical Trial/ AGS15E/ AGS-15ME)

Study Title

ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer (NCT01963052)

Trial Description

All subjects will receive a single intravenous infusion of AGS15E once weekly for 3 weeks of every 4 weeks. A cycle is 4 weeks. Subjects will continue treatment until disease progression, intolerability of AGS15E, investigator decision, or consent withdrawal.

The study design will follow a modified Continual Reassessment Method (CRM). A disease assessment will be conducted every 8 weeks (Q8W) +/- 7 days until disease progression.

A data review team (DRT) will review cumulative unaudited data on an interim basis to explore additional doses and/or schedules, or the expansion of existing cohorts. Doses intermediate to those predefined in the protocol may be explored with DRT endorsement.All subjects will receive a single intravenous infusion of AGS15E once weekly for 3 weeks of every 4 weeks. A cycle is 4 weeks.

Subjects will continue treatment until disease progression, intolerability of AGS15E, investigator decision, or consent withdrawal.The study design will follow a modified Continual Reassessment Method (CRM). A disease assessment will be conducted every 8 weeks (Q8W) +/- 7 days until disease progression.
A data review team (DRT) will review cumulative unaudited data on an interim basis to explore additional doses and/or schedules, or the expansion of existing cohorts. Doses intermediate to those predefined in the protocol may be explored with DRT endorsement.

This trial is sponsored by Astellas Pharma Inc® in collaboration with Seattle Genetics®.

Study Data

  • Condition: Metastatic Urothelial Cancer
  • Interventions:
    • Drugs used in this trial
      • AGS-15E
  • Phase: I
  • Enrollment: 93
  • Start: November 2013
  • Estimated Completion: November 2017
  • Last verified: June 2017
  • Last Updated: June 2017

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: August 23, 2017
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2017 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar